These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 33409846)

  • 1. Active vitamin D supplementation and COVID-19 infections: review.
    Farid N; Rola N; Koch EAT; Nakhoul N
    Ir J Med Sci; 2021 Nov; 190(4):1271-1274. PubMed ID: 33409846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19.
    Kumar R; Rathi H; Haq A; Wimalawansa SJ; Sharma A
    Virus Res; 2021 Jan; 292():198235. PubMed ID: 33232783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of vitamin D in preventing of COVID-19 infection, progression and severity.
    Ali N
    J Infect Public Health; 2020 Oct; 13(10):1373-1380. PubMed ID: 32605780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D.
    Peng MY; Liu WC; Zheng JQ; Lu CL; Hou YC; Zheng CM; Song JY; Lu KC; Chao YC
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19.
    Xu Y; Baylink DJ; Chen CS; Reeves ME; Xiao J; Lacy C; Lau E; Cao H
    J Transl Med; 2020 Aug; 18(1):322. PubMed ID: 32847594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supplementation with vitamin D in the COVID-19 pandemic?
    Hadizadeh F
    Nutr Rev; 2021 Jan; 79(2):200-208. PubMed ID: 32679589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection.
    Ahmed F
    Front Immunol; 2020; 11():590459. PubMed ID: 33362771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between vitamin D supplementation or serum vitamin D level and susceptibility to SARS-CoV-2 infection or COVID-19 including clinical course, morbidity and mortality outcomes? A systematic review.
    Grove A; Osokogu O; Al-Khudairy L; Mehrabian A; Zanganeh M; Brown A; Court R; Taylor-Phillips S; Uthman OA; McCarthy N; Kumar S; Clarke A
    BMJ Open; 2021 May; 11(5):e043737. PubMed ID: 34049903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths.
    Grant WB; Lahore H; McDonnell SL; Baggerly CA; French CB; Aliano JL; Bhattoa HP
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32252338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
    Ramasamy S; Subbian S
    Clin Microbiol Rev; 2021 Jun; 34(3):. PubMed ID: 33980688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
    Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK
    Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D: A Potential Mitigation Tool for the Endemic Stage of the COVID-19 Pandemic?
    Briceno Noriega D; Savelkoul HFJ
    Front Public Health; 2022; 10():888168. PubMed ID: 35757617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.